company background image
NXS

Next ScienceASX:NXS Stock Report

Market Cap

AU$249.4m

7D

2.9%

1Y

3.7%

Updated

20 Oct, 2021

Data

Company Financials +
NXS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NXS Overview

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms.

Price History & Performance

Summary of all time highs, changes and price drops for Next Science
Historical stock prices
Current Share PriceAU$1.26
52 Week HighAU$1.10
52 Week LowAU$2.06
Beta0.54
1 Month Change-8.70%
3 Month Change-23.17%
1 Year Change3.70%
3 Year Changen/a
5 Year Changen/a
Change since IPO-6.67%

Recent News & Updates

Shareholder Returns

NXSAU Medical EquipmentAU Market
7D2.9%3.0%1.7%
1Y3.7%-6.5%20.2%

Return vs Industry: NXS exceeded the Australian Medical Equipment industry which returned -6.5% over the past year.

Return vs Market: NXS underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is NXS's price volatile compared to industry and market?
NXS volatility
NXS Beta0.54
Industry Beta0.57
Market Beta1

Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: NXS's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aJudith Mitchellhttps://www.nextscience.com

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal.

Next Science Fundamentals Summary

How do Next Science's earnings and revenue compare to its market cap?
NXS fundamental statistics
Market CapUS$186.50m
Earnings (TTM)-US$9.42m
Revenue (TTM)US$6.30m

29.6x

P/S Ratio

-19.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NXS income statement (TTM)
RevenueUS$6.30m
Cost of RevenueUS$1.23m
Gross ProfitUS$5.07m
ExpensesUS$14.49m
Earnings-US$9.42m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 28, 2021

Earnings per share (EPS)-0.048
Gross Margin80.49%
Net Profit Margin-149.42%
Debt/Equity Ratio0%

How did NXS perform over the long term?

See historical performance and comparison

Valuation

Is Next Science undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NXS (A$1.26) is trading below our estimate of fair value (A$5.75)

Significantly Below Fair Value: NXS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NXS is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: NXS is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NXS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NXS is overvalued based on its PB Ratio (11.6x) compared to the AU Medical Equipment industry average (5x).


Future Growth

How is Next Science forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

74.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NXS's revenue (65.6% per year) is forecast to grow faster than the Australian market (5.4% per year).

High Growth Revenue: NXS's revenue (65.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NXS is forecast to be unprofitable in 3 years.


Past Performance

How has Next Science performed over the past 5 years?

-14.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NXS is currently unprofitable.

Growing Profit Margin: NXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NXS is unprofitable, and losses have increased over the past 5 years at a rate of 14.9% per year.

Accelerating Growth: Unable to compare NXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: NXS has a negative Return on Equity (-58.6%), as it is currently unprofitable.


Financial Health

How is Next Science's financial position?


Financial Position Analysis

Short Term Liabilities: NXS's short term assets ($15.7M) exceed its short term liabilities ($1.6M).

Long Term Liabilities: NXS's short term assets ($15.7M) exceed its long term liabilities ($1.5M).


Debt to Equity History and Analysis

Debt Level: NXS is debt free.

Reducing Debt: NXS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NXS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NXS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Next Science current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NXS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Judith Mitchell

4.17yrs

Tenure

US$277,242

Compensation

Ms. Judith Mitchell, M.B.A, serves as Managing Director and Chief Executive Officer of Next Science Limited since August 2017 and serves as its Executive Director since October 20, 2017. Previously, Ms. Mi...


CEO Compensation Analysis

Compensation vs Market: Judith's total compensation ($USD277.24K) is below average for companies of similar size in the Australian market ($USD547.68K).

Compensation vs Earnings: Judith's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NXS's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: NXS's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NXS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

Next Science Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Next Science Limited
  • Ticker: NXS
  • Exchange: ASX
  • Founded: 2012
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$249.447m
  • Shares outstanding: 197.97m
  • Website: https://www.nextscience.com

Location

  • Next Science Limited
  • The Zenith Building, Tower A
  • Suite 1902
  • Chatswood
  • New South Wales
  • 2067
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:35
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.